PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to ...
Please provide your email address to receive an email when new articles are posted on . A prospective comparative case series of 50 patients implanted bilaterally ...
PanOptix, the first and only advanced trifocal lens for U.S. patients undergoing cataract surgery, will be showcased in educational events and clinical data presentations First-ever analyses on IOLs ...
Please provide your email address to receive an email when new articles are posted on . PanOptix, which is already available in more than 70 countries, has been shown to deliver a combination of near, ...
MIDDLETOWN, Ky., Sept. 26, 2019 /PRNewswire-PRWeb/ -- Frank Burns, MD, the medical director of Middletown Eye Center was one of the first surgeons in Kentucky to implant the Alcon Acrysof IQ PanOptix ...
The FINANCIAL — Basel, June 18, 2018 Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the ...
PHOENIX, Sept. 3, 2019 /PRNewswire-PRWeb/ -- Barnet Dulaney Perkins Eye Center, an American Vision Partners affiliate, is the first practice in Arizona to provide a new solution for patients with ...
More than three million cataract surgeries performed in Europe annually[1] Basel, Switzerland, June 16, 2015 - Alcon, the global leader in eye care and a division of Novartis, has received European CE ...
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients ...
GENEVA--(BUSINESS WIRE)-- Alcon (ALC), the global leader in eye care dedicated to helping people see brilliantly, announced today the introduction of Clareon ® PanOptix ® Pro intraocular lens (IOL) ...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results